HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Cullinan Therapeutics (NASDAQ: CGEM) and raised the price target from $30 to $35. This adjustment reflects a positive outlook for the company in the market.